1-(3-Chloropropylsulfonyl)azetidine | 1154926-38-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: 1-(3-Chloropropylsulfonyl)azetidine
• CAS: 1154926-38-1
• 化学式: C₆H₁₂ClNO₂S
• 分子量: 197.686
• InChiKey: UKPYXRKRUSTCOA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  methyl 2,3,4,9-tetrahydro-1H-carbazole-6-carboxylate 、 1-(3-Chloropropylsulfonyl)azetidine 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 Methyl 9-[3-(azetidin-1-ylsulfonyl)propyl]-5,6,7,8-tetrahydrocarbazole-3-carboxylate
  参考文献：
  名称：

  Discovery of highly potent small molecule Hepatitis C Virus entry inhibitors

  摘要：

  Novel, highly potent small molecule HCV entry inhibitors are reported. The SAR exploration of a hit molecule identified from screening of a compound library led to the identification of highly potent compounds with IC50 values of <5 nM in the tissue culture HCV infectious assay. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.09.019

文献信息

• [EN] DERIVATIVES OF SUBSTITUTED FUSED RING CYCLOINDOLES AND METHODS OF THEIR USE<br/>[FR] DÉRIVÉS DE CYCLOINDOLES À CYCLE CONDENSÉ SUBSTITUÉ ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ITHERX PHARMACEUTICALS INC

  公开号：WO2009103022A1

  公开（公告）日：2009-08-20

  Disclosed herein are derivatives of substituted fused ring cycloindole useful, inter alia, in combating Hepatitis C infection and entry into cells.

  本文披露了替代融合环环己吲哚衍生物，可用于抑制丙型肝炎感染并阻止进入细胞。
• PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS
  申请人：Marsilje Thomas H.

  公开号：US20110112063A1

  公开（公告）日：2011-05-12

  The invention provides novel pyrimidine derivatives of formula I and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-IR) or analplastic lymphoma kinase (ALK).

  本发明提供了式I的新型嘧啶衍生物及其制药组合物，以及使用这些化合物的方法。例如，本发明的嘧啶衍生物可用于治疗、改善或预防对IGF-IR或ALK抑制有反应的疾病。
• Compounds and compositions as kinase inhibitors
  申请人：Marsilje Thomas H.

  公开号：US08859574B2

  公开（公告）日：2014-10-14

  The invention provides novel pyrimidine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-1R) or analplastic lymphoma kinase (ALK).

  本发明提供了新型嘧啶衍生物及其制药组合物，以及使用这些化合物的方法。例如，本发明的嘧啶衍生物可用于治疗、改善或预防对胰岛素样生长因子（IGF-1R）或无形淋巴瘤激酶（ALK）抑制有反应的疾病。
• COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
  申请人：Marsilje Thomas H.

  公开号：US20130310361A1

  公开（公告）日：2013-11-21

  The invention provides novel pyrimidine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-1R) or analplastic lymphoma kinase (ALK).

  本发明提供新型嘧啶衍生物及其药物组合物，以及使用这些化合物的方法。例如，本发明的嘧啶衍生物可用于治疗、改善或预防对胰岛素样生长因子（IGF-1R）或无形淋巴瘤激酶（ALK）抑制有反应的疾病。
• Pyrimidine derivatives as kinase inhibitors
  申请人：Marsilje, III Thomas H.

  公开号：US08519129B2

  公开（公告）日：2013-08-27

  The invention provides novel pyrimidine derivatives of formula I and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-IR) or analplastic lymphoma kinase (ALK).

  该发明提供了公式I的新型嘧啶衍生物及其制药组合物，以及使用这些化合物的方法。例如，该发明的嘧啶衍生物可以用于治疗、改善或预防对IGF-IR或ALK的抑制有反应的情况。